News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation To Present Highly Anticipated Phase III Data In IPF And COPD At American Thoracic Society International Conference


4/30/2014 8:18:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

For media outside UK, U.S. and Canada

Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of idiopathic pulmonary fibrosis (IPF), will be presented at the 2014 American Thoracic Society (ATS) International Conference taking place 16 – 21 May in San Diego. IPF is a rare, debilitating and fatal lung disease for which treatment options are limited.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES